Halozyme Therapeutics (HALO) 14.57 $HALO
Halozyme Therapeutics Provides An Update On Anticipated Milestones For 2015 At The 33rd Annual J. P. Morgan Healthcare Conference
PR Newswire - Mon Jan 12, 8:00AM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today provided an update on anticipated 2015 corporate milestones.
HALO: 14.57 (+0.54)
'Mad Money' Lightning Round: Be Careful Investing in Google
at The Street - Sat Jan 10, 5:00AM CST
Cramer was bearish on Cliffs Natural Resources, Royal Dutch Shell and Halozyme Therapeutics.
AUO: 5.73 (-0.03), RDS.A: 62.93 (-1.29), HALO: 14.57 (+0.54), EVEP: 16.90 (-1.64), GOOGL: 497.06 (-3.66), CLF: 7.70 (+0.55)
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Jan 09, 7:19PM CST
Earnings season is back and Cramer will be watching Alcoa and CSX, among others.
AUO: 5.73 (-0.03), MNST: 111.96 (-5.08), LM: 53.07 (-0.72), INTC: 36.60 (-0.16), SLB: 78.05 (-3.17), JPM: 58.83 (-0.51), TGT: 76.63 (+0.20), DD: 74.41 (+0.91), GOOGL: 497.06 (-3.66), PPG: 226.25 (-0.72), HD: 104.42 (-0.47), INCY: 73.30 (+1.27), IR: 62.20 (+0.45), WFC: 52.05 (-0.63), CLF: 7.70 (+0.55), GSK: 42.93 (+0.13), CSX: 33.91 (-0.49), MS: 36.37 (-0.51), AGEN: 6.17 (+0.88), AA: 16.17 (+0.06), LEN: 47.07 (+0.28), HALO: 14.57 (+0.54), GS: 185.07 (-2.28), EVEP: 16.90 (-1.64), RDS.A: 62.93 (-1.29), WEN: 9.93 (unch)
Nasdaq stocks posting largest percentage increases
AP - Thu Jan 08, 5:10PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
LOXO: 11.35 (-0.45), ELOS: 10.92 (+0.05), AMBA: 61.90 (+0.07), RGEN: 25.30 (+1.06), ADXS: 12.09 (+0.79), NBIX: 29.51 (+1.22), PDFS: 16.94 (-0.56), HALO: 14.57 (+0.54), VLCCF: 5.08 (+0.49), PKT: 8.35 (-0.07), ARNA: 5.65 (+0.22)
Halozyme up on upgrade
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 11:14AM CST
HALO: 14.57 (+0.54)
Critical Alerts For Kinder Morgan, Halozyme Therapeutics, MannKind, BP and Union Pacific Released By InvestorsObserver
PR Newswire - Thu Jan 08, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for KMI, HALO, MNKD, BP and UNP.
KMI: 41.61 (-0.20), HALO: 14.57 (+0.54), BP: 36.05 (-0.53), MNKD: 5.49 (-0.27), UNP: 113.97 (-1.01)
Rallying on Street: Special Research on Dick's Sporting, Monsanto, Halozyme, Janus Capital and Sony
PR Newswire - Thu Jan 08, 6:30AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Dick's Sporting (NYSE: DKS), Monsanto (NYSE: MON), Halozyme (NASDAQ: HALO), Janus Capital (NYSE: JNS), and Sony (NYSE: SNE). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
HALO: 14.57 (+0.54), MON: 119.56 (+0.52), DKS: 53.93 (+0.39), JNS: 16.91 (-0.09), SNE: 21.36 (+0.02)
Halozyme Provides Agenda Highlights For Analyst And Investor Meeting
PR Newswire - Wed Jan 07, 7:00AM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today will review the PEGPH20 development program and provide 2015 financial guidance during a meeting for analysts and investors in New York at 10:00 a.m. ET/ 7:00 a.m. PT.
HALO: 14.57 (+0.54)
Halozyme Therapeutics To Present At The 33rd Annual J.P. Morgan Healthcare Conference
PR Newswire - Tue Jan 06, 3:30PM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2015 at 4:00 p.m. PT / 7:00 p.m. ET. Dr. Helen Torley, President and Chief Executive Officer, will provide a corporate overview.
HALO: 14.57 (+0.54), JPM: 58.83 (-0.51)
Halozyme Therapeutics Appoints Athena Countouriotis, M.D. as Chief Medical Officer
PR Newswire - Mon Jan 05, 7:30AM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the appointment of Athena Countouriotis, M.D., as Chief Medical Officer where she will be responsible for directing Halozyme's research, clinical development and regulatory activities.
HALO: 14.57 (+0.54)
Halozyme Therapeutics To Host Analyst And Investor Meeting
PR Newswire - Tue Dec 30, 8:00AM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced it will be hosting a meeting for analysts and investors in New York on Wednesday, January 7, 2015 at 10:00 a.m. ET/ 7:00 a.m. PT. During the meeting, Halozyme's senior management and a physician expert will discuss the following topics:
HALO: 14.57 (+0.54)
Halozyme's PEGPH20 tagged an Orphan Drug in Europe
Seeking Alpha - at Seeking Alpha - Fri Dec 19, 9:31AM CST
HALO: 14.57 (+0.54)
Halozyme Receives European Orphan Drug Designation For PEGylated Recombinant Human Hyaluronidase PH20 For Pancreatic Cancer
PR Newswire - Fri Dec 19, 7:30AM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the European Commission, acting on the recommendation from the Committee for Orphan Medicinal Products of the European Medicines Agency (EMA), has designated PEGylated recombinant human hyaluronidase (PEGPH20) an orphan medicinal product for the treatment of pancreatic cancer. Halozyme is currently conducting a Phase 2 study on the treatment of metastatic pancreatic cancer with PEGPH20 in combination with gemcitabine and nab-paclitaxel (ABRAXANE®). In October 2014, the Company disclosed that the U.S. Food and Drug Administration also granted Orphan Drug designation for PEGPH20 for the treatment of pancreatic cancer.
HALO: 14.57 (+0.54)
Halozyme Up on Collaboration and Licensing Deal with J&J - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 18, 5:48PM CST
Shares of Halozyme (HALO) jumped after announcing a worldwide collaboration and license agreement with Johnson & Johnson (JNJ).
JNJ: 104.58 (-0.36), HALO: 14.57 (+0.54), PFE: 32.77 (+0.12), AMGN: 156.22 (+0.49)
Deal Street: Analyst Coverage on Visteon, Halozyme, Coca-Cola, Groupon and Barrick Gold
PR Newswire - Thu Dec 18, 8:30AM CST
Moments ago, Realtime Equities released new analyst updates concerning several important developing situations including Visteon (NYSE: VC), Halozyme (NASDAQ: HALO), Coca-Cola (NYSE: KO), Groupon (NASDAQ: GRPN), and Barrick Gold (NYSE: ABX). Realtime Equities is the leader in realtime news, commentary and analysis - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
KO: 42.64 (-0.39), VC: 104.50 (-0.19), HALO: 14.57 (+0.54), ABX: 11.33 (+0.34), GRPN: 7.42 (-0.32)
Janssen Biotech licenses Halozyme's Enhanze technology
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 8:30AM CST
JNJ: 104.58 (-0.36), HALO: 14.57 (+0.54)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 8:13AM CST
CERS: 6.22 (+0.07), FRO: 4.63 (+0.69), KNDI: 12.87 (-0.20), GFI: 5.96 (+0.42), CLF: 7.70 (+0.55), NVGN: 2.25 (-0.03), ASPX: 59.91 (+0.57), DRIV: 25.44 (+0.13), SID: 1.98 (-0.06), HALO: 14.57 (+0.54), VOLC: 17.87 (unch), POZN: 6.94 (-0.85), ICLD: 2.70 (-0.10), TASR: 25.84 (-0.43), DGLY: 12.90 (-0.71), SBGL: 9.69 (+0.47)
Halozyme Therapeutics Enters A Global Collaboration With Janssen To Develop And Commercialize Subcutaneous Products Using ENHANZE(TM) Technology
PR Newswire - Wed Dec 17, 8:00AM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that it has entered into a worldwide Collaboration and License Agreement with Janssen Biotech, Inc. (Janssen) for the purpose of developing and commercializing products combining proprietary Janssen compounds with Halozyme's ENHANZE(TM) technology. ENHANZE is based on a proprietary recombinant human hyaluronidase enzyme (rHuPH20) that temporarily modifies hyaluronan, a component of the extracellular matrix, to aid in the dispersion and absorption of other injected therapeutic drugs.
HALO: 14.57 (+0.54)
United States Vaccines, Skin Replacement Products and Biologicals Manufacturing Industry Analytics 2014-2021 - Market to reach $39.5 billion by 2021
M2 - Mon Dec 15, 8:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/s847lc/vaccines_skin) has announced the addition of Plunkett Research Ltd's new report "Vaccines, Skin Replacement Products and Biologicals Manufacturing Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021" to their offering. Vaccines, Skin Replacement Products and Biologicals Manufacturing Industry (U.S.) to reach $39.5 billion by 2021 Vital industry-specific data including metrics, benchmarks, historic numbers, growth rates and forecasts that will save countless hours of research. Core Benefits to Customer: 1. Comprehensive overview of an industry's financial results, ratios, vital statistics and metrics in one package 2. Complete benchmarking of the industry and its top companies 3. Deep industry and company financials This Report Features: 1. Historical data 2. Revenue forecasts, growth rates and CAGR 3. Operating ratios 4. Complete data for benchmarking a company to its industry and to specific leading companies 5. Benchmarking this industry to all U.S. industries 6. Deep profiles and financial histories/operating ratios for up to ten top U.S.-based companies Designed to benefit: - Analysis and Financial Modeling - Investment Professionals - Lenders - M&A Advisors - Appraisers - Consultants Key Data: Industry Summary - Revenues historical through 2013 - Revenues projected through 2021 - Employee Count 2007-2013 - Annual Growth Rate 2013 - CAGR 2006 through 2013 - CAGR 2014 through 2021 - Top U.S. Companies Employment and Establishments - Number of Firms 2007-2013 - Number of Establishments 2007-2013 - Employees, 2007-2013 - Average Annual Sales per Firm & per Establishment 2007-2013 - Sales per Employee Average Annual Operating Ratios - Revenue Compared to All Industries - Expenses Compared to All Industries - Profits & Income Taxes Compared to All Industries Benchmarks This Industry Compared to All Industries - Comparison of Revenues, Profits and Taxes to All Industries Industry Results, Publicly-Held Companies (U.S.), Average for all Companies - Industry Income Statement, Balance Sheet, Cash Flow Statement, 2008-2013 Top Companies Profiled & Ranked - Anika Therapeutics Inc - CSL Behring LLC - Emergent BioSolutions Inc - Halozyme Therapeutics Inc - LifeCell Corporation - Lifecore Biomedical Inc - MiMedx Group Inc - Organogenesis Inc - RTI Biologics Inc - Zoetis Inc For more information visit http://www.researchandmarkets.com/research/s8...cines_skin Source: Plunkett Research Ltd
ZTS: 43.42 (-0.83), RTIX: 5.13 (+0.06), HALO: 14.57 (+0.54), EBS: 27.84 (+0.24), ANIK: 39.62 (-0.08), MDXG: 8.79 (-0.48)
Biotech Equities Update - Biogen Idec, ACADIA Pharma, Halozyme Therapeutics, Neurocrine Biosciences, and Bluebird Bio
PR Newswire - Fri Dec 12, 7:50AM CST
Investor-Edge has initiated coverage on the following equities: Biogen Idec Inc. (NASDAQ: BIIB), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Halozyme Therapeutics Inc. (NASDAQ: HALO), Neurocrine Biosciences Inc. (NASDAQ: NBIX), and Bluebird Bio Inc. (NASDAQ: BLUE). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Thursday, December 11, 2014, the NASDAQ Composite ended at 4,708.16, up 0.52%, the Dow Jones Industrial Average advanced 0.36%, to finish the day at 17,596.34, and the S&P 500 closed at 2,035.33, up 0.45%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 806.11, up 0.26%, with the index also advancing 8.67% in the previous three months. Register for your complimentary reports on these five stocks at:
BLUE: 101.95 (-1.68), BIIB: 347.84 (+5.50), ACAD: 34.25 (+0.88), NBIX: 29.51 (+1.22), HALO: 14.57 (+0.54)
Halozyme Therapeutics Provides An Update On Anticipated Milestones For 2015 At The 33rd Annual J. P. Morgan Healthcare Conference
PR Newswire - Mon Jan 12, 8:00AM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today provided an update on anticipated 2015 corporate milestones.
HALO: 14.57 (+0.54)
'Mad Money' Lightning Round: Be Careful Investing in Google
at The Street - Sat Jan 10, 5:00AM CST
Cramer was bearish on Cliffs Natural Resources, Royal Dutch Shell and Halozyme Therapeutics.
AUO: 5.73 (-0.03), RDS.A: 62.93 (-1.29), HALO: 14.57 (+0.54), EVEP: 16.90 (-1.64), GOOGL: 497.06 (-3.66), CLF: 7.70 (+0.55)
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Jan 09, 7:19PM CST
Earnings season is back and Cramer will be watching Alcoa and CSX, among others.
AUO: 5.73 (-0.03), MNST: 111.96 (-5.08), LM: 53.07 (-0.72), INTC: 36.60 (-0.16), SLB: 78.05 (-3.17), JPM: 58.83 (-0.51), TGT: 76.63 (+0.20), DD: 74.41 (+0.91), GOOGL: 497.06 (-3.66), PPG: 226.25 (-0.72), HD: 104.42 (-0.47), INCY: 73.30 (+1.27), IR: 62.20 (+0.45), WFC: 52.05 (-0.63), CLF: 7.70 (+0.55), GSK: 42.93 (+0.13), CSX: 33.91 (-0.49), MS: 36.37 (-0.51), AGEN: 6.17 (+0.88), AA: 16.17 (+0.06), LEN: 47.07 (+0.28), HALO: 14.57 (+0.54), GS: 185.07 (-2.28), EVEP: 16.90 (-1.64), RDS.A: 62.93 (-1.29), WEN: 9.93 (unch)
Nasdaq stocks posting largest percentage increases
AP - Thu Jan 08, 5:10PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
LOXO: 11.35 (-0.45), ELOS: 10.92 (+0.05), AMBA: 61.90 (+0.07), RGEN: 25.30 (+1.06), ADXS: 12.09 (+0.79), NBIX: 29.51 (+1.22), PDFS: 16.94 (-0.56), HALO: 14.57 (+0.54), VLCCF: 5.08 (+0.49), PKT: 8.35 (-0.07), ARNA: 5.65 (+0.22)
Halozyme up on upgrade
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 11:14AM CST
HALO: 14.57 (+0.54)
Critical Alerts For Kinder Morgan, Halozyme Therapeutics, MannKind, BP and Union Pacific Released By InvestorsObserver
PR Newswire - Thu Jan 08, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for KMI, HALO, MNKD, BP and UNP.
KMI: 41.61 (-0.20), HALO: 14.57 (+0.54), BP: 36.05 (-0.53), MNKD: 5.49 (-0.27), UNP: 113.97 (-1.01)
Rallying on Street: Special Research on Dick's Sporting, Monsanto, Halozyme, Janus Capital and Sony
PR Newswire - Thu Jan 08, 6:30AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Dick's Sporting (NYSE: DKS), Monsanto (NYSE: MON), Halozyme (NASDAQ: HALO), Janus Capital (NYSE: JNS), and Sony (NYSE: SNE). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
HALO: 14.57 (+0.54), MON: 119.56 (+0.52), DKS: 53.93 (+0.39), JNS: 16.91 (-0.09), SNE: 21.36 (+0.02)
Halozyme Provides Agenda Highlights For Analyst And Investor Meeting
PR Newswire - Wed Jan 07, 7:00AM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today will review the PEGPH20 development program and provide 2015 financial guidance during a meeting for analysts and investors in New York at 10:00 a.m. ET/ 7:00 a.m. PT.
HALO: 14.57 (+0.54)
Halozyme Therapeutics To Present At The 33rd Annual J.P. Morgan Healthcare Conference
PR Newswire - Tue Jan 06, 3:30PM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2015 at 4:00 p.m. PT / 7:00 p.m. ET. Dr. Helen Torley, President and Chief Executive Officer, will provide a corporate overview.
HALO: 14.57 (+0.54), JPM: 58.83 (-0.51)
Halozyme Therapeutics Appoints Athena Countouriotis, M.D. as Chief Medical Officer
PR Newswire - Mon Jan 05, 7:30AM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the appointment of Athena Countouriotis, M.D., as Chief Medical Officer where she will be responsible for directing Halozyme's research, clinical development and regulatory activities.
HALO: 14.57 (+0.54)
Halozyme Therapeutics To Host Analyst And Investor Meeting
PR Newswire - Tue Dec 30, 8:00AM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced it will be hosting a meeting for analysts and investors in New York on Wednesday, January 7, 2015 at 10:00 a.m. ET/ 7:00 a.m. PT. During the meeting, Halozyme's senior management and a physician expert will discuss the following topics:
HALO: 14.57 (+0.54)
Halozyme's PEGPH20 tagged an Orphan Drug in Europe
Seeking Alpha - at Seeking Alpha - Fri Dec 19, 9:31AM CST
HALO: 14.57 (+0.54)
Halozyme Receives European Orphan Drug Designation For PEGylated Recombinant Human Hyaluronidase PH20 For Pancreatic Cancer
PR Newswire - Fri Dec 19, 7:30AM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the European Commission, acting on the recommendation from the Committee for Orphan Medicinal Products of the European Medicines Agency (EMA), has designated PEGylated recombinant human hyaluronidase (PEGPH20) an orphan medicinal product for the treatment of pancreatic cancer. Halozyme is currently conducting a Phase 2 study on the treatment of metastatic pancreatic cancer with PEGPH20 in combination with gemcitabine and nab-paclitaxel (ABRAXANE®). In October 2014, the Company disclosed that the U.S. Food and Drug Administration also granted Orphan Drug designation for PEGPH20 for the treatment of pancreatic cancer.
HALO: 14.57 (+0.54)
Halozyme Up on Collaboration and Licensing Deal with J&J - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 18, 5:48PM CST
Shares of Halozyme (HALO) jumped after announcing a worldwide collaboration and license agreement with Johnson & Johnson (JNJ).
JNJ: 104.58 (-0.36), HALO: 14.57 (+0.54), PFE: 32.77 (+0.12), AMGN: 156.22 (+0.49)
Deal Street: Analyst Coverage on Visteon, Halozyme, Coca-Cola, Groupon and Barrick Gold
PR Newswire - Thu Dec 18, 8:30AM CST
Moments ago, Realtime Equities released new analyst updates concerning several important developing situations including Visteon (NYSE: VC), Halozyme (NASDAQ: HALO), Coca-Cola (NYSE: KO), Groupon (NASDAQ: GRPN), and Barrick Gold (NYSE: ABX). Realtime Equities is the leader in realtime news, commentary and analysis - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
KO: 42.64 (-0.39), VC: 104.50 (-0.19), HALO: 14.57 (+0.54), ABX: 11.33 (+0.34), GRPN: 7.42 (-0.32)
Janssen Biotech licenses Halozyme's Enhanze technology
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 8:30AM CST
JNJ: 104.58 (-0.36), HALO: 14.57 (+0.54)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 8:13AM CST
CERS: 6.22 (+0.07), FRO: 4.63 (+0.69), KNDI: 12.87 (-0.20), GFI: 5.96 (+0.42), CLF: 7.70 (+0.55), NVGN: 2.25 (-0.03), ASPX: 59.91 (+0.57), DRIV: 25.44 (+0.13), SID: 1.98 (-0.06), HALO: 14.57 (+0.54), VOLC: 17.87 (unch), POZN: 6.94 (-0.85), ICLD: 2.70 (-0.10), TASR: 25.84 (-0.43), DGLY: 12.90 (-0.71), SBGL: 9.69 (+0.47)
Halozyme Therapeutics Enters A Global Collaboration With Janssen To Develop And Commercialize Subcutaneous Products Using ENHANZE(TM) Technology
PR Newswire - Wed Dec 17, 8:00AM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that it has entered into a worldwide Collaboration and License Agreement with Janssen Biotech, Inc. (Janssen) for the purpose of developing and commercializing products combining proprietary Janssen compounds with Halozyme's ENHANZE(TM) technology. ENHANZE is based on a proprietary recombinant human hyaluronidase enzyme (rHuPH20) that temporarily modifies hyaluronan, a component of the extracellular matrix, to aid in the dispersion and absorption of other injected therapeutic drugs.
HALO: 14.57 (+0.54)
United States Vaccines, Skin Replacement Products and Biologicals Manufacturing Industry Analytics 2014-2021 - Market to reach $39.5 billion by 2021
M2 - Mon Dec 15, 8:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/s847lc/vaccines_skin) has announced the addition of Plunkett Research Ltd's new report "Vaccines, Skin Replacement Products and Biologicals Manufacturing Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021" to their offering. Vaccines, Skin Replacement Products and Biologicals Manufacturing Industry (U.S.) to reach $39.5 billion by 2021 Vital industry-specific data including metrics, benchmarks, historic numbers, growth rates and forecasts that will save countless hours of research. Core Benefits to Customer: 1. Comprehensive overview of an industry's financial results, ratios, vital statistics and metrics in one package 2. Complete benchmarking of the industry and its top companies 3. Deep industry and company financials This Report Features: 1. Historical data 2. Revenue forecasts, growth rates and CAGR 3. Operating ratios 4. Complete data for benchmarking a company to its industry and to specific leading companies 5. Benchmarking this industry to all U.S. industries 6. Deep profiles and financial histories/operating ratios for up to ten top U.S.-based companies Designed to benefit: - Analysis and Financial Modeling - Investment Professionals - Lenders - M&A Advisors - Appraisers - Consultants Key Data: Industry Summary - Revenues historical through 2013 - Revenues projected through 2021 - Employee Count 2007-2013 - Annual Growth Rate 2013 - CAGR 2006 through 2013 - CAGR 2014 through 2021 - Top U.S. Companies Employment and Establishments - Number of Firms 2007-2013 - Number of Establishments 2007-2013 - Employees, 2007-2013 - Average Annual Sales per Firm & per Establishment 2007-2013 - Sales per Employee Average Annual Operating Ratios - Revenue Compared to All Industries - Expenses Compared to All Industries - Profits & Income Taxes Compared to All Industries Benchmarks This Industry Compared to All Industries - Comparison of Revenues, Profits and Taxes to All Industries Industry Results, Publicly-Held Companies (U.S.), Average for all Companies - Industry Income Statement, Balance Sheet, Cash Flow Statement, 2008-2013 Top Companies Profiled & Ranked - Anika Therapeutics Inc - CSL Behring LLC - Emergent BioSolutions Inc - Halozyme Therapeutics Inc - LifeCell Corporation - Lifecore Biomedical Inc - MiMedx Group Inc - Organogenesis Inc - RTI Biologics Inc - Zoetis Inc For more information visit http://www.researchandmarkets.com/research/s8...cines_skin Source: Plunkett Research Ltd
ZTS: 43.42 (-0.83), RTIX: 5.13 (+0.06), HALO: 14.57 (+0.54), EBS: 27.84 (+0.24), ANIK: 39.62 (-0.08), MDXG: 8.79 (-0.48)
Biotech Equities Update - Biogen Idec, ACADIA Pharma, Halozyme Therapeutics, Neurocrine Biosciences, and Bluebird Bio
PR Newswire - Fri Dec 12, 7:50AM CST
Investor-Edge has initiated coverage on the following equities: Biogen Idec Inc. (NASDAQ: BIIB), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Halozyme Therapeutics Inc. (NASDAQ: HALO), Neurocrine Biosciences Inc. (NASDAQ: NBIX), and Bluebird Bio Inc. (NASDAQ: BLUE). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Thursday, December 11, 2014, the NASDAQ Composite ended at 4,708.16, up 0.52%, the Dow Jones Industrial Average advanced 0.36%, to finish the day at 17,596.34, and the S&P 500 closed at 2,035.33, up 0.45%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 806.11, up 0.26%, with the index also advancing 8.67% in the previous three months. Register for your complimentary reports on these five stocks at:
BLUE: 101.95 (-1.68), BIIB: 347.84 (+5.50), ACAD: 34.25 (+0.88), NBIX: 29.51 (+1.22), HALO: 14.57 (+0.54)
